Truth and facts will not stop HEB pumpers from saying silly things about "shorts" and their imaginary hedge fund.
HEB's share price has been losing about a penny per week.
And, it does not have many pennies left to work with.
True, there is no substantial market for Alferon and it is a cumbersome product to manufacture.
Today's press release is a reminder that Alferon is actually a blood product, and thus its manufacture falls under a high degree of scrutiny by the FDA.
" Hemispherx was recently informed by BioLife Plasma Services, a subsidiary of major U.S. player Baxalta, that it was, without cause, terminating its sole source contract with Hemispherx prior to the termination date because it was departing that particular area of its business being conducted under the d/b/a Penn Plasma."
"recently" is a bit vague. It would be helpful to know exactly when HEB learned of this issue.
After a few more quarters go buy with no success in Alferon sales, HEB will move back to pumping Ampligen for CFS or whatever exotic disease is in the headlines at the time.
"The shorts are way, way too powerful and have far too much influence."
Short interest in HEB is only 68k shares or 0.02% of the float.
Only someone with a very defective brain would argue that shorts are playing any role in HEB's current share price.
On this message board, you can find this post from bones:
""bonesnj0 • Jul 21, 2009 2:50 PM Flag
43users liked this postsusers disliked this posts7Reply
Bought 5K more @ 2.96 "
From the 10K in Mar 2000: "The number of shares of the registrant's Common Stock outstanding
as of December 31, 1999 was 27,806,572" That was the era when JohnnyD was buying $17 shares.
From the 10K in Mar 2009: "The number of shares of the registrant's Common Stock outstanding as of March 3, 2009 was 80,881,135." That was the state of affairs at the start of the big 2009 pump for a doomed NDA.
10K from Mar 2010: "The number of shares of the registrant’s Common Stock outstanding as of March 1, 2010 was 132,840,970." That shows the dilution that happened when HEB took advantage of the inflated share price due to the doomed NDA. HEB raised enough money to do another phase 2 study then, but chose to give out bonuses instead.
10K from Mar 2012" The number of shares of the registrant’s Common Stock outstanding as of March 1, 2010 was 132,840,970." There was actually no dilution between the end of the 2009 pump and the dawn of the 2012 pump for another doomed NDA.
10K from Mar 2013: "The number of shares of the registrant’s Common Stock outstanding as of March 1, 2013 was 166,784,590." Which reflects the dilution that happened during the 2012 pump.
10Q from Aug 2015: "246,886,840 shares of common stock were outstanding as of August 1, 2015." This reflects the desperate at-the-market dumping that HEB has done since the second FDA rejection to try to stay afloat and pay generous salaries, cash bonuses and "consulting fees" to Carter & Equels.
Every year the announce that they are reducing the quorum as a one time measure, I think that they have to phrase it that way for legal reasons. But with the reduced quorum they usually get the votes that they want.
However, interestingly, in recent years, the majority of shareholders have voted against the executive compensation plans. But those are non-binding votes and HEB ignores them and keeps doling out generous pay, bonuses and "consulting fees" to Carter & Equels despite what the shareholders say.
Will another dose of Alferon ever be sold in Carter's lifetime?
That is an open question.
It would be good to see some money on real research for real treatments rather than see any further money wasted on Ampligen.
"this is going to $3.00 midterm or sooner"
HEB will only see $3 again if it does a large reverse-split.
Even during the last grand pump in 2012, (for a doomed NDA), HEB briefly touched $1 for only a day.
And there has been so much more dilution since then.
The days of $1+ share prices for HEB are well behind it, (other than through a reverse-split).
And what royalties have they had from their patents? Let's look at the recent 10Q:
"The following table summarizes our royalty revenues for the three and six months ended June 30, 2015 and 2014 (in thousands).
Three Months Ended
June 30, 2015
Total royalty revenues 117"
$117K in quarterly revenues does not justify a market capitalization of $249 million.
The revenues from Hextend are vanishing.
Most of their revenue, such as it comes from government grants, and they do not justify the share price either, and some of the grants are expiring. These grants are not the ingredients of a sustainable business model.
"Total grant revenue for the three and six months ended June 30, 2015 were $1.4 million and $2.1 million, respectively, representing increases of approximately 125% and 75% over grant revenues for the respective periods in the prior year. Grant revenue for the three and six months ended June 30, 2015 included $659,000 and $1.3 million, respectively, recognized by Asterias from a grant awarded by the California Institute for Regenerative Medicine (“CIRM”), $206,000 and $ 310,000, respectively from three grants awarded to us by the National Institutes of Health (“NIH”) of which two will expire in August 2015 and the third in May 2016, and $563,000 and $467,000, respectively, recognized by Cell Cure Neurosciences from grants awarded by the Office of the Chief Scientist of Israel (“OCS”) during the three and six months ended June 30, 2015. The six months grant revenues compared to the three months grant revenues from the OCS as of June 30, 2015 are lower, primarily due to an $89,000 adjustment in the first quarter and fluctuating foreign currency exchange rates."
The price tends to go up or down at the end of the day most likely due to day traders closing out their positions.
Nothing sinister either way.
" Buy at 15 or 18, doesn't matter much in the long term - the trick is to get in before approval because if you feel regretful about not getting in at 10 when it is 16 now -you'll really regret not getting in at 16 when the iron strikes."
How does Johnny sleep at night?
Johnny Dodson, I only give that long winded version because in the past., when I said "I am not with a hedge fund and I am not short HEB," pumpers such as yourself, Mike and Natalie will come up with other accusations such as "You work for a competitor!" or other such nonsense.
I have formed a firm opinion of HEB. But I am not biased due to any financial considerations.
Now, can you give an explanation of why someone would say that they bought at $17 and exhorted others to buy at those ridiculous levels and to keep pumping the stock during its years long slide to $0.17 on this board and on CFS patient boards that does not involve some compensation for promoting HEB?
"aren't making any money these days. Are you??"
I've never made any money from HEB in any direct or indirect way. I have never had any position in HEB stock or options, and I have no affiliation with any hedge fund or other entity in the world of equities or finance. I have never and never will receive any compensation for posting here or anywhere on the internet. I have no association with any competitor of HEB and have never had any benefit either directly or indirectly from any share price rise or fall of HEB.
I'm just here because I came across the HEB story and was astounded and disgusted by it, and am happy to use spare moments to counter lies told by the paid pumpers and to warn unwary investors about HEB.